miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 5, 2026

Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider

View original at globenewswire.com
Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider Austin, United States, Feb…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Hospitals accounted for the largest share of 53.12% in 2025

    80% confidence

  • The Human Vaccines Market is driven by the rising awareness of preventive healthcare, expansion of national immunization programs, and rising cases of infectious and chronic diseases

    80% confidence

  • The market is challenged by high development costs, complex manufacturing processes, and strict regulatory requirements

    80% confidence

  • The Asia Pacific Human Vaccines Market is the fastest-growing globally, projected to register a CAGR of 5.89% during 2026–2033

    80% confidence

  • Geriatric vaccines are expected to grow at the fastest CAGR of 6.98% during 2026–2033

    80% confidence

  • Government vaccination programs are an essential factor in the development of the market

    80% confidence

  • Research & Academic Institutes are forecasted to register the fastest CAGR of 7.21% during 2026–2033

    80% confidence

  • mRNA vaccines are expected to grow at the fastest CAGR of 7.12% during 2026–2033

    80% confidence

  • HPV vaccines are anticipated to record the fastest CAGR of 7.34% through 2026–2033

    80% confidence

  • COVID-19 vaccines dominated with a 31.25% share in 2025

    80% confidence

  • Intradermal delivery is projected to expand at the fastest CAGR of 6.45% during the forecast period

    80% confidence

  • Intramuscular vaccines accounted for the highest market share of 46.32% in 2025

    80% confidence

  • North America dominated the Human Vaccines Market, accounting for a 34.56% market share in 2025

    80% confidence

  • The Human Vaccines Market size was valued at USD 44.26 billion in 2025 and is expected to reach USD 62.45 billion by 2033, growing at a CAGR of 4.43% during the forecast period of 2026-2033

    80% confidence

  • Online Pharmacy is expected to grow at the fastest CAGR of 6.78% during 2026–2033

    80% confidence

  • Hospital Pharmacy held the largest share of 45.87% in 2025

    80% confidence

  • Adult vaccines held the largest share of 39.61% in 2025

    80% confidence

  • Inactivated vaccines held the largest market share of 28.74% in 2025

    80% confidence

  • The U.S. Human Vaccines Market is expected to grow from USD 11.72 billion in 2025 to USD 15.17 billion by 2033, registering a CAGR of 3.30% during the forecast period

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Human Vaccines Market Size to Reach USD 62.45 Billion by 2033, Driven by Expanding Immunization Programs – SNS Insider — Source | Via News | es.VIA.NEWS